ArticlePharmaceuticals (Basel, Switzerland)2026
Real-World Effectiveness and Safety of Upadacitinib Versus Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A Retrospective Cohort Study.
Ömer Karakoyun et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.